Two Mechanistic Pathways for Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura. A Report From the SERF-TTP Research Group and the RADAR Project

Journal of the American College of Cardiology

Volumn 50, Issue 12, 2007, Pages 1138-1143

  Bennett, Charles L ^a   Kim, Benjamin ^a   Zakarija, Anaadriana ^a   Bandarenko, Nicholas ^b   Pandey, Dilip K ^c   Buffie, Charlie G ^a   McKoy, June M ^a   Tevar, Amul D ^c   Cursio, John F ^c   Yarnold, Paul R ^a   Kwaan, Hau C ^l   De Masi, Davide ^a   Sarode, Ravindra ^f   Raife, Thomas J ^d   Kiss, Joseph E ^e   Raisch, Dennis W ^g   Davidson, Charles ^a   Sadler, J Evan ^h   Ortel, Thomas L ⁱ   Zheng, X Long ^j   Kato, Seiji ^k   Matsumoto, Masanori ^k   Uemura, Masahito ^k   Fujimura, Yoshihiro ^k   more..

^a JESSE BROWN VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g University of New Mexico   (United States)

^h WASHINGTON UNIVERSITY   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k NARA MEDICAL UNIVERSITY   (Japan)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PYRIDINE DERIVATIVE; TICLOPIDINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY FUNCTION; LABORATORY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PLASMAPHERESIS; PRIORITY JOURNAL; SURVIVAL; SURVIVAL RATE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PLASMA EXCHANGE; PLATELET AGGREGATION INHIBITORS; PROBABILITY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; PYRIDINES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL ANALYSIS; TICLOPIDINE;

EID: 34548542028     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.04.093     Document Type: Article

References (35)

1. Amorosi E., and Ultmann J. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 45 (1966) 139-159
2. Andersohn F., Bronder E., Klimpel A., and Garbe E. Proportion of drug-related serious rare blood dyscrasias: estimates from the Berlin Case-Control Surveillance Study. Am J Hematol 77 (2004) 316-318
3. Bennett C.L., Connors J.M., Carwile J.M., et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 342 (2000) 1773-1777
4. Bennett C.L., Weinberg P.D., Rozenberg-Ben-Dror K., Yarnold P.R., Kwaan H.C., and Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 128 (1998) 541-544
5. Zakarija A., Bandarenko N., Pandey D.K., et al. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 35 (2004) 533-537
6. Bennett C.L., Kiss J.E., Weinberg P.D., Pinevich A.J., Green D., Kwaan H.C., and Feldman M.D. Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet 352 (1998) 1036-1037
7. Savi P., Combalbert J., Gaich C., et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 72 (1994) 313-317
8. Clopidogrel (Plavix) [Package insert]. New York, NY: Bristol-Myers Squibb and Sanofi-Synthelabo; January 2006. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3418. Accessed August 6, 2007.
9. Furlan M., Robles R., Galbusera M., et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339 (1998) 1578-1584
10. Kokame K., Matsumoto M., Soejima K., et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 99 (2002) 11902-11907
11. Zheng X.L., Chung D., Takayama T.K., et al. Structure of von Willebrand Factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276 (2001) 41059-41063
12. Tsai H.M., Rice L., Sarode R., Chow T.W., and Moake J.L. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 132 (2000) 794-799
13. Bennett C.L., Nebeker J.R., Lyons A., et al. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA 293 (2005) 2131-2140
14. Bennett C.L., Nebeker J.R., Yarnold P.R., et al. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med 167 (2007) 1041-1049
15. Mauro M., Zlatopolskiy A., Raife T.J., and Laurence J. Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signalling cascades. Br J Haematol 124 (2004) 200-210
16. Zheng X.L., Kaufman R.M., Goodnough L.T., and Sadler J.E. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 103 (2004) 4043-4049
17. Zakarija A., Kwaan H.C., Bandarenko N., et al. Preliminary results from the Surveillance, Epidemiology & Risk Factors for TTP (SERF-TTP) group: a prospective case-control study of idiopathic TTP. (abstr). Blood 108 (2006) 1063
18. Kato S., Matsumoto M., Matsuyama T., Isonishi A., Hiura H., and Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 46 (2006) 1444-1452
19. Gerritsen H.E., Turecek P.L., Schwarz H.P., Lammle B., and Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 82 (1999) 1380-1381
20. Tsai H.M., and Lian E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339 (1998) 1585-1594
21. Tripodi A., Chantarangkul V., Bohm M., et al. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2 (2004) 1601-1609
22. Yarnold P.R., and Soltysik R.C. Optimal Data Analysis: A Guidebook With Software for Windows (2004), American Psychological Association Books, Washington, DC
23. Raife T., Atkinson B., Montgomery R., Vesely S., and Friedman K. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion 44 (2004) 146-150
24. Yarnold P.R., Soltysik R.C., and Bennett C.L. Predicting in-hospital mortality of patients AIDS-related Pneumocystis carinii pneumonia: an example of hierarchically classification tree analysis. Stat Med 16 (1997) 1451-1463
25. Vesely S.K., George J.N., Lammle B., et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 102 (2003) 60-68
26. Matsumoto M., Kokame K., Soejima K., et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 103 (2004) 1305-1310
27. Qu L., and Kiss J.E. Thrombotic microangiopathy in transplantation and malignancy. Semin Thromb Hemost 31 (2005) 691-699
28. Evens A., Kwaan H.C., Kaufman D.B., and Bennett C.L. TTP/HUS occurring in a pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology. Transplantation 74 (2002) 885-887
29. Raife T.J., Lentz S.R., Atkinson B.S., Vesely S.K., and Hessner M.J. Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood 99 (2002) 437-442
30. Patel T.N., Kreindel M., and Lincoff A.M. Clopidogrel and ticlopidine mediation of TTP: a report. J Invasive Cardiol 18 (2006) E211-E213
31. Bennett C.L., Luminari S., Nissenson A.R., et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 351 (2004) 1403-1408
32. Salliere D., Kassler-Taub K.B., Trontell A.E., et al. Clopidogrel and thrombotic thrombocytopenic purpura. N Engl J Med 343 (2000) 1191-1194
33. Jonas S., and Grieco G. Editorial comment-an approach to the estimation of the risk of TTP during clopidogrel therapy. Stroke 35 (2004) 537-538
34. Hankey G.J. Clopidogrel and thrombotic thrombocytopenic purpura. Lancet 356 (2000) 269-270
35. Majhail A.S., and Lichtin A.N. Clopidogrel and thrombotic thrombocytopenic purpura: no clear case for causality. Cleve Clin J Med 70 (2003) 466-470